Business Context and Reporting Period
Company: Champions Oncology, Inc. (CSBR)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended October 31, 2025
Business Overview: The Company is a technology-enabled research organization providing drug discovery and development services via its TumorGraft Technology Platform (PDX models) and Translational Oncology Solutions (TOS). It operates in a single reportable segment.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Oct 31, 2025 | 6 Months Ended Oct 31, 2025 | Balance Sheet (Oct 31, 2025) |
|---|---|---|---|
| Oncology Revenue | $15,035 | $29,030 | - |
| Net Income (Loss) | $237 | $(230) | - |
| Net Income (Loss) Attributable to Common Shares | $268 | $(169) | - |
| Operating Income (Loss) | $185 | $(342) | - |
| Cash and Cash Equivalents | - | - | $8,516 |
| Total Assets | - | - | $30,162 |
| Total Liabilities | - | - | $25,931 |
| Stockholders' Equity | - | - | $4,231 |
| Working Capital | - | - | $(809) |
| Accumulated Deficit | - | - | $(80,121) |
Cash Flow (Six Months Ended Oct 31, 2025):
- Operating Activities: $(1,135) thousand
- Investing Activities: $(288) thousand
- Financing Activities: $154 thousand
- Net Decrease in Cash: $(1,269) thousand
Material Changes vs. Prior Period
- Revenue Growth: Oncology revenue increased 11.5% year-over-year (YoY) for the quarter ($15.0M vs. $13.5M) and 5.4% for the six-month period ($29.0M vs. $27.6M). Growth was driven by improved bookings-to-revenue conversion and fewer study cancellations.
- Profitability Shift: The Company reported a net income of $237,000 for the quarter, compared to $728,000 in the prior year quarter. However, for the six-month period, the Company reported a net loss of $230,000, a significant decline from net income of $2.0 million in the prior year six-month period.
- Expense Increases:
- R&D Expenses: Increased 54.9% YoY for the quarter and 49.5% for six months, driven by higher outsourced lab services, compensation, and investment in the Corellia subsidiary.
- G&A Expenses: Increased 57.4% YoY for the quarter and 25.5% for six months, primarily due to executive leadership changes and IT infrastructure investments.
- Revenue Mix: TOS Data License revenue generated $157,000 (quarter) and $468,000 (six months), whereas there was no such revenue in the prior year periods. Conversely, "Other TOS Revenue" (flow cytometry and SaaS) declined significantly due to a strategic de-emphasis on flow cytometry.
- Liquidity: Cash decreased from $9.8M to $8.5M over the six-month period. The Company reported negative working capital of $809,000.
Outlook, Risks, and Management Commentary
- Liquidity Outlook: Management believes cash on hand ($8.5M) and expected cash flows are adequate to fund operations through at least December 2026. No assurance is given regarding the ability to raise additional capital if required.
- Strategic Focus: The Company is expanding its data licensing business and investing in Corellia (target discovery). It anticipates cost structure improvements as radiolabeling work transitions from outsourced vendors to internal labs.
- Lease Termination: The Company terminated its Milan, Italy lease early in Q2 2025, recording a $9,000 gain and reducing lease liabilities by $117,000. The Company will no longer utilize a physical site in Italy.
- Risks: As a smaller reporting company, the filing does not detail specific risk factors but references the 2025 Annual Report. General risks include economic uncertainty, supply chain disruptions, and the inability to raise capital on acceptable terms.
- Stock-Based Compensation: Total expense was $249,000 for the quarter and $457,000 for six months. Remaining unrecognized expense is $3.8 million, with $1.7 million tied to performance-based awards.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $8.5M cash balance against the negative operating cash flow of $1.1M for the six-month period and the negative working capital position.
- Revenue Sustainability: Assess the durability of the revenue increase driven by "fewer study cancellations" and the impact of the strategic de-emphasis on flow cytometry services.
- Expense Trajectory: Monitor the continued rise in R&D and G&A expenses, particularly those related to the Corellia subsidiary and executive leadership changes, to ensure they align with future revenue growth.
- Deferred Revenue: Note the decrease in deferred revenue from $15.4M to $12.3M, which contributed to the negative operating cash flow; verify if this indicates a slowdown in upfront billings.
- Performance-Based Compensation: Review the $1.7M in unrecognized stock-based compensation tied to performance targets, as this represents a contingent future expense dependent on achieving specific financial goals.